AMAG Pharmaceuticals, Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Lexington MA United States (1981)
Status: Acquired by Covis (2020) → now Advanz Pharma (2015)

Organization Overview

First Clinical Trial
2004
NCT00255424
First Marketed Drug
1996
ferumoxides (feridex I.V.)
First NDA Approval
1996
ferumoxides (feridex I.V.)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

AMAG Pharmaceuticals, Inc. | AMAG PHARMA USA | AMAG PHARMS INC | Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.

Active Ingredients

Marketed Drugs (6)

Key: AMAG Pharmaceuticals, Inc. (5) Acquired (1)

bremelanotide (Vyleesi) (2019 NDA)

ferumoxides (feridex I.V.) (1996 NDA)

ferumoxsil (Gastromark) (1996)

ferumoxytol (feraheme) (2009 NDA)

hydroxyprogesterone (Delalutin) (2011)

prasterone (intrarosa) (2016)

Drugs in Phase 4 Trials (5)

acetylsalicylic acid (aspirin) (1 trial)

bremelanotide (Vyleesi) (2 trials)

ferrous sulfate (6 trials)

ferumoxytol (feraheme) (28 trials)

sucroferric oxyhydroxide (Venofer) (3 trials)

Drugs in Phase 3 Trials (10)

Key: AMAG Pharmaceuticals, Inc. (6) Acquired (4)

butoconazole (Femstat) (2 trials)

clindamycin (cleocin) (2 trials)

estradiol (progynon depot) (1 trial)

ferric carboxymaltose (Injectafer) (1 trial)

ferrous fumarate (1 trial)

hydroxyprogesterone (Delalutin) (4 trials)

iron sucrose (venofer) (2 trials)

prasterone (intrarosa) (3 trials)

progestin (1 trial)

vitamin c (2 trials)

Drugs in Phase 2 Trials (14)

Key: AMAG Pharmaceuticals, Inc. (7) Acquired (7)

autologous mononuclear stem cell (2 trials)

autologous umbilical cord blood (3 trials)

carbomer (1 trial)

ciraparantag (8 trials)

danazol (danocrine) (1 trial)

dehydroepiandrosterone (1 trial)

digoxin immune fab (ovine) (DigiFab) (1 trial)

diphenhydramine (benadryl) (1 trial)

epoetin (Epogen) (1 trial)

glycerin (1 trial)

lidocaine (xylocaine) (1 trial)

mineral oil (1 trial)

palm oil (1 trial)

polycarbophil (1 trial)

Drugs in Phase 1 Trials (3)

Key: AMAG Pharmaceuticals, Inc. (2) Acquired (1)

insulin lispro (humalog) (1 trial)

moxifloxacin (avelox) (1 trial)

ondansetron (zofran) (1 trial)

Drugs in Other Trials (1)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 4)

Anemia, Iron-Deficiency (Phase 4)

Aneurysm (Phase 1)

Atherosclerosis (Phase 1)

Atrophy (Phase 3)

Brain Neoplasms (Phase 1)

Breast Neoplasms (Phase 3)

Cardiovascular Diseases (Phase 2)

Communicable Diseases (Phase 3)

Deficiency Diseases (Phase 4)

Disease (Phase 4)

Esophageal Neoplasms (Phase 1)

Hemorrhage (Phase 4)

Hypokinesia (Phase 4)

Infections (Phase 3)

Intracranial Aneurysm (Phase 1)

Intracranial Arteriosclerosis (Phase 1)

Kidney Diseases (Phase 4)

Menorrhagia (Phase 4)

Nausea (Phase 1)

Peripheral Arterial Disease (Phase 2)

Peripheral Vascular Diseases (Phase 2)

Premature Birth (Phase 3)

Psychomotor Agitation (Phase 2)

Renal Insufficiency, Chronic (Phase 4)

Restless Legs Syndrome (Phase 2)

Sexual Dysfunctions, Psychological (Phase 4)

Syndrome (Phase 3)

Urinary Tract Infections (Phase 3)

Uterine Hemorrhage (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 60
  • # of Trial APIs: 33